Neuroprotective agents for clinical trials in ALS: A systematic assessment

Neurology

Volumn 67, Issue 1, 2006, Pages 20-27

  Traynor, B J ^a,g   Bruijn, L ^b   Conwit, R ^c   Beal, F ^d   O'Neill, G ^e   Fagan, S C ^f   Cudkowicz, M E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ALS Association   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e BIOGEN   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ADENOVIRUS VECTOR; AEOL 10150; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOPTOSIS INHIBITOR; ARIMOCLOMOL; ARUNDIC ACID; ARYLBUTYRIC ACID DERIVATIVE; CEFTRIAXONE; CELASTROL; GLATIRAMER; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; HYDROXYLAMINE; LENALIDOMIDE; MEMANTINE; MINOCYCLINE; NIMESULIDE; RILUZOLE; SOMATOMEDIN BINDING PROTEIN 1; TALAMPANEL; TAMOXIFEN; TCH 346; THALIDOMIDE; TREHALOSE; UBIDECARENONE; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT;

ABSENCE OF SIDE EFFECTS; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATAXIA; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; GASTROINTESTINAL SYMPTOM; HEMOPHILIA; HUMAN; IMMUNOMODULATION; MEDICAL LITERATURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; TERATOGENICITY; TRANSGENIC MOUSE; VERTIGO; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; EVALUATION; METHODOLOGY; OUTCOME ASSESSMENT;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS; EVALUATION STUDIES; HUMANS; NEUROPROTECTIVE AGENTS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 33746849034     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000223353.34006.54     Document Type: Review

References (86)

1. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688-1700.
2. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004;27:723-749.
3. Heemskerk J. High throughput drug screening. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(suppl 1):19-21.
4. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003;60:1234-1240.
5. Rothstein JD. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol 2003;53:423-426.
6. Miller RG, Bradley W, Cudkowicz M, et al. Phase II/III controlled trial of TCH 346 in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6(suppl 1):13.
7. Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Riluzole-Tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:9-18.
8. Graf M, Ecker D, Horowski R, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm 2005;112:649-660
9. Cleveland DW. From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 1999;24:515-520.
10. Patel M, Day BJ. Metalloporphyrin class of therapeutic catalytic antioxidants. Trends Pharmacol Sci 1999;20:359-364.
11. Crow JP, Calingasan NY, Chen J, Hill JL, Beal MF. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 2005;58:258-265.
12. Batulan Z, Shinder GA, Minotti S, et al. High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. J Neurosci 2003;23:5789-5798.
13. Hargitai J, Lewis H, Boros I, et al. Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun 2003;307:689-695.
14. Kieran D, Kalmar B, Dick JR, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10:402-405.
15. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25.
16. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
17. Ince P, Stout N, Shaw P, et al. Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol Appl Neurobiol 1993;19:291-299.
18. Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73-77.
19. Nau R, Prange HW, Muth P, et al. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob Agents Chemother 1993;37:1518-1524.
20. Guglielmo BJ, Luber AD, Paletta D Jr., Jacobs RA. Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis 2000;30:205-207.
21. Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992;140:691-707.
22. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002;26:459-470.
23. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:1341-1357.
24. Westerheide SD, Bosman JD, Mbadugha BN, et al. Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 2004;279:56053-56060.
25. Kipiani K, Kiaei M, Chen J, Calingasan NY, Beal MF. Celastrol blocks motor neuron cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2004;90(suppl 1):92.
26. Do TQ, Schultz JR, Clarke CF. Enhanced sensitivity of ubiquinone-deficient mutants of Saccharomyces cerevisiae to products of autoxidized polyunsaturated fatty acids. Proc Natl Acad Sci USA 1996;93:7534-7539.
27. Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 1998;95:8892-8897.
28. Ferrante KL, Shefner J, Zhang H, et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 2005;65:1834-1836.
29. Crone C, Gabriel G, Wise TN. Non-herbal nutritional supplements-the next wave: a comprehensive review of risks and benefits for the C-L psychiatrist. Psychosomatics 2001;42:285-299.
30. Haverkamp LJ, Smith RG, Appel SH. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 1994;36:253-254.
31. Angelov DN, Waibel S, Guntinas-Lichius O, et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2003;100:4790-4795.
32. Perez NB, Haenggeli C, Rothstein JD. Vaccination with COP1 derivative does not alter disease progression in a SOD1 G93A transgenic ALS mouse. Abstr Soc Neurosci 2005;213.9. Abstract.
33. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group Neurology 1997;49:1621-1630.
34. Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998;51:583-586.
35. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003;301:839-842.
36. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003;101:2963-2972.
37. Terro F, Yardin C, Esclaire F, Ayer-Lelievre C, Hugon J. Mild kainate toxicity produces selective motoneuron death with marked activation of CA(2+)-permeable AMPA/kainate receptors. Brain Res 1998;809:319-324.
38. Kornhuber J, Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 1995;195:137-139.
39. Pasinelli P, Belford ME, Lennon N, et al. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 2004;43:19-30.
40. Pasinelli P, Houseweart MK, Brown RH Cleveland DW. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000;97:13901-13906.
41. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10:268-278.
42. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-78.
43. Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 2003;53:267-270.
44. Van Den BL, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002;13:1067-1070.
45. Gordon PH, Moore DH, Gelinas DF, et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004;62:1845-1847.
46. Slusher BS, Vornov JJ, Thomas AG, et al. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 1999;5:1396-1402.
47. Almer G, Guegan C, Teismann P, et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 2001;49:176-185.
48. Bezzi P, Carmignoto G, Pasti L, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998;391:281-285.
49. Facino RM, Carini M, Aldini G. Antioxidant activity of nimesulide and its main metabolites. Drugs 1993;46(suppl 1):15-21.
50. Pompl PN, Ho L, Bianchi M, et al. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 2003;17:725-727.
51. Cudkowicz ME, Shefner JM, Schoenfeld D, et al. Clinical trial of celecoxib in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(suppl 2):25-26.
52. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-1711.
53. Clement AM, Nguyen MD, Roberts EA, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003;302:113-117.
54. Nilsson M, Hansson E, Ronnback L. Interactions between valproate, glutamate, aspartate, and GABA with respect to uptake in astroglial primary cultures. Neurochem Res 1992;17:327-332.
55. Katsumata S, Tateishi N, Kagamiishi Y, et al. Inhibitory effect of ONO-2506 on GABAA receptor disappearance in cultured astrocytes and ischemic brain. Abstr Soc Neurosci 1999;843:11. Abstract.
56. Shimoda T, Tateishi N, Shintaku K, et al. ONO-2506, a novel astrocyte modulating agent, suppresses the increase of COX-2 and iNOS mRNA expression in cultured astrocytes and ischemic brain. Abstr Soc Neurosci 1998;384:13. Abstract.
57. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-591.
58. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Doseranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347:1425-1431.
59. Couratier P, Sindou P, Esclaire F, Louvel E, Hugon J. Neuroprotective effects of riluzole in ALS CSF toxicity. Neuroreport 1994;5:1012-1014.
60. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.
61. Leigh PN, Anderton BH, Dodson A, Gallo JM, Swash M, Power DM. Ubiquitinated deposits in anterior horn cells in motor neurone disease. Neurosci Lett 1988;93:197-203.
62. Corcoran LJ, Mitchison TJ, Liu Q. A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Curr Biol 2004;14:488-492.
63. Mercuri E, Bertini E, Messina S, et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 2004;14:130-135.
64. Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005;93:1087-1098.
65. Barker PB, Artemov D, Raymond GV, Horská A, Moser HW. Detection of 4-phenylbutyrate in the human brain by in vivo Proton MR Spectroscopy. Proceedings of the ISMRM 8th Scientific Meeting and Exhibition; Denver, CO; 2000.
66. Hu JH, Zhang H, Wagey R, Krieger C, Pelech SL. Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J Neurochem 2003;85:432-442.
67. Brooks B, Sanjak M, Roelke K, et al. Phase 2B randomized dose-ranging clinical trial of tamoxifen, a selective estrogen receptor modulator [SERM], in ALS: sensitivity analyses of discordance between survival and functional outcomes with long-term follow-up. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6(suppl 1):118.
68. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-138.
69. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-394.
70. Greenway MJ, Andersen PM, Russ C, et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet 2006 Feb 26 [Epub ahead of print].
71. Mujagic H, Chabner BA, Mujagic Z. Mechanisms of action and potential therapeutic uses of thalidomide. Croat Med J 2002;43:274-285.
72. Kiaei M, Petri S, Kipiani K, et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006;26:2467-2473.
73. Alexander LN, Wilcox CM. A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. AIDS Res Hum Retroviruses 1997;13:301-304.
74. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-557.
75. Romisch K. A cure for traffic jams: small molecule chaperones in the endoplasmic reticulum. Traffic 2004;5:815-820.
76. Drachman DB, Frank K, Dykes-Hoberg M, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2002;52:771-778.
77. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-350.
78. Groeneveld GJ, Veldink JH, van dT I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53:437-445.
79. Miller RG, Moore DH, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-848.
80. Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 2000;11:2491-2493.
81. Kuther G, Struppler A. Therapeutic trial with N-acetylcysteine in amyotrophic lateral sclerosis. Adv Exp Med Biol 1987;209:281-284.
82. Cudkowicz ME, Pastusza KA, Sapp PC, et al. Survival in transgenic ALS mice does not vary with CNS glutathione peroxidase activity. Neurology 2002;59:729-734.
83. Kirkinezos IG, Hernandez D, Bradley WG, Moraes CT. Regular exercise is beneficial to a mouse model of amyotrophic lateral sclerosis. Ann Neurol 2003;53:804-807.
84. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61:456-464.
85. Kirkinezos IG, Hernandez D, Bradley WG, Moraes CT. An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J Neurochem 2004;88:821-826.
86. ALS Association. Clinical research pilot study request for proposals. Available at: http://www.alsa.org/news/article.cfm?id=682&CFID= 1785756&CFTOKEN=32724346